ArticleBMC cancer2017

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

Bernies van der Hiel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.